Omalizumab - Urticaria
You are here : Home > Formulary Search > Omalizumab - Urticaria
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Documentation
NICE Technology Appraisal
Policy Statement
PAD Profile
ChemicalSubstance :
Omalizumab
Indication :
Urticaria
Group Name :
Keywords :
Brand Names Include :
Xolair, Omlyclo
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3
Committee Recommendations (1)
The PCN supports the use of Omalizumab for previously treated chronic spontaneous urticaria in line with NICE TA339 (June 2015)
Prescribing would be by specialists in dermatology, immunology or allergy, and notification of initiation will be via the Blueteq initiation and continuation forms. Omalizumab will be considered RED on the traffic light system
Prescribing would be by specialists in dermatology, immunology or allergy, and notification of initiation will be via the Blueteq initiation and continuation forms. Omalizumab will be considered RED on the traffic light system
Other Indications
Below are listed other indications that Omalizumab is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Urticaria.